FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380082565> ?p ?o ?g. }

• W4380082565 endingPage "418" @default.
• W4380082565 startingPage "416" @default.
• W4380082565 abstract "Introduction: In the Phase 3 POLARIX study (NCT03274492), polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), with a similar safety profile in pts aged 18–80 years with previously untreated DLBCL (Tilly et al., 2022). Combination regimens may be associated with higher rates of toxicity in elderly pts. We report the efficacy and safety of Pola-R-CHP versus R-CHOP in pts aged ≥70 years enrolled in POLARIX. Methods: POLARIX methods were described by Tilly et al. (2022). Pts with previously untreated DLBCL were randomized 1:1 to receive 6 cycles of Pola-R-CHP or R-CHOP, plus 2 cycles of rituximab. This analysis focused on pts aged ≥70 years at enrollment. Results: Overall, 284 pts were analyzed for efficacy (Pola-R-CHP, n = 141; R-CHOP, n = 143) and 280 pts were analyzed for safety (Pola-R-CHP, n = 137; R-CHOP, n = 143). Median age was 74 years (range 70–80), and 69.7% had an International Prognostic Index score of 3–5. Most pts in either arm received all 6 doses of polatuzumab vedotin or vincristine (88.3% and 91.6% in the Pola-R-CHP and R-CHOP arms, respectively). At data cutoff (June 28, 2021; median follow-up: 24.2 months), the risk of progression, relapse or death was lower with Pola-R-CHP versus R-CHOP (hazard ratio [HR] 0.64; 95% confidence interval [CI]: 0.41–0.99) (Table). Death by any cause occurred in 14.2% and 19.6% of pts treated with Pola-R-CHP and R-CHOP, respectively. Overall survival (OS) and disease-free survival (DFS) results are presented in the Table. Safety profiles were generally comparable for Pola-R-CHP versus R-CHOP, including rates of Grade 3–5 adverse events (AEs), Grade 5 AEs, serious AEs, peripheral neuropathy (any grade), neutropenia (Grade 3–4), and infection (Grade 3–4) (Table). Conclusions: Pola-R-CHP and R-CHOP demonstrated similar safety profiles in pts aged ≥70 years with previously untreated DLBCL. The risk-benefit profile favored Pola-R-CHP versus R-CHOP. Encore Abstract - previously submitted to ASCO 2023 The research was funded by: The POLARIX study (NCT03274492) was sponsored by F. Hoffmann-La Roche Ltd. and Genentech, Inc. Third-party editorial assistance, under the direction of the authors, was provided by Leen Al-Mohammad, BSc, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd. Keywords: Aggressive B-cell non-Hodgkin lymphoma, Combination Therapies Conflicts of interests pertinent to the abstract. B. Hu Consultant or advisory role: ADC Therapeutics, BeiGene, MorphoSys, Janssen Research funding: Genentech, Inc., BeiGene P. M. Reagan Consultant or advisory role: Kite (a Gilead Company) Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc., Seattle Genetics L. H. Sehn Consultant or advisory role: Celgene, AbbVie, Seattle Genetics, TG Therapeutics, Janssen, Amgen, F. Hoffmann-La Roche Ltd./Genentech, Inc., Gilead Sciences, Lundbeck, Apobiologix, Karyopharm Therapeutics, Kite (a Gilead Company), Merck, Takeda, Teva, AstraZeneca, Acerta Pharma, MorphoSys, Incyte, Debiopharm Group, Sandoz-Novartis, Genmab, Verastem Honoraria: Amgen, Apobiologix, AbbVie, Celgene, Gilead Sciences, Janssen-Ortho, Karyopharm Therapeutics, Kite (a Gilead Company), Lundbeck, Merck, F. Hoffmann-La Roche Ltd./Genentech, Inc., Seattle Genetics, Takeda, Teva, TG Therapeutics, AstraZeneca, Acerta Pharma, MorphoSys, Incyte, Debiopharm Group, Sandoz-Novartis, Verastem, Genmab Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc., Teva J. Sharman Consultant or advisory role: TG Therapeutics, Genentech, Inc., AbbVie, Acerta Pharma/AstraZeneca, BeiGene, Bristol-Myers Squibb, Merck Research funding: Pharmacyclics, Genentech, Inc., Celgene, Acerta Pharma, Gilead Sciences, Seattle Genetics, TG Therapeutics, Merck, Takeda M. Hertzberg Consultant or advisory role: Janssen, F. Hoffmann-La Roche Ltd., Takeda, Gilead Sciences, BeiGene, Novartis Honoraria: F. Hoffmann-La Roche Ltd./Genentech, Inc., Janssen Educational grants: Takeda C. Herbaux Honoraria: F. Hoffmann-La Roche Ltd., Janssen-Cilag, AbbVie, Gilead Sciences Research funding: Takeda Educational grants: Janssen-Cilag, AbbVie, F. Hoffmann-La Roche Ltd. L. Molina Consultant or advisory role: AbbVie Educational grants: AbbVie, Janssen, Novartis D. Maruyama Honoraria: MSD, Zenyaku Kogyo, Bristol-Myers Squibb Japan, Nippon Shinyaku, Takeda, Janssen, Eisai, Celgene, Kyowa Kirin, Ono Pharmaceutical, Mundipharma, Chugai, Daiichi Sankyo, Asahi Kasei, AstraZeneca, Synmosa Biopharma Research funding: Amgen Astellas BioPharma, Astellas Pharma, Otsuka, Novartis, Kyowa Kirin, Sanofi, Bristol-Myers Squibb, Chugai, Ono Pharmaceutical, Celgene, Janssen, Eisai, Takeda, MSD P. Smolewski Consultant or advisory role: F. Hoffmann-La Roche Ltd. Poland, Takeda Honoraria: F. Hoffmann-La Roche Ltd. Poland, Takeda Educational grants: F. Hoffmann-La Roche Ltd. Poland, Takeda Other remuneration: F. Hoffmann-La Roche Ltd. Poland (Expert Testimony) F. Stenner Consultant or advisory role: Bristol-Myers Squibb, MSD, F. Hoffmann-La Roche Ltd., Novartis, Celgene, Janssen Honoraria: Bristol-Myers Squibb, MSD, F. Hoffmann-La Roche Ltd., Novartis, Celgene, Janssen Research funding: Bristol-Myers Squibb, Takeda Educational grants: Bristol-Myers Squibb, MSD, F. Hoffmann-La Roche Ltd., Novartis, Celgene, Janssen V. Craine Employment or leadership position: F. Hoffmann-La Roche Ltd. R. Kothari Employment or leadership position: F. Hoffmann-La Roche Ltd./Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd./Genentech, Inc. J. Hirata Employment or leadership position: Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd. D. Sahin Employment or leadership position: F. Hoffmann-La Roche Ltd. Stock ownership: F. Hoffmann-La Roche Ltd. M. Sugidono Employment or leadership position: F. Hoffmann-La Roche Ltd./Genentech, Inc. Stock ownership: F. Hoffmann-La Roche Ltd./Genentech, Inc. C. Lee Employment or leadership position: F. Hoffmann-La Roche Ltd. Stock ownership: F. Hoffmann-La Roche Ltd. H. Tilly Consultant or advisory role: F. Hoffmann-La Roche Ltd., Incyte, Celgene/Bristol-Myers Squibb Honoraria: Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd. Research funding: F. Hoffmann-La Roche Ltd./Genentech, Inc. Educational grants: F. Hoffmann-La Roche Ltd., Janssen" @default.
• W4380082565 created "2023-06-10" @default.
• W4380082565 creator A5003078312 @default.
• W4380082565 creator A5005349514 @default.
• W4380082565 creator A5007004125 @default.
• W4380082565 creator A5012158679 @default.
• W4380082565 creator A5013007045 @default.
• W4380082565 creator A5020361669 @default.
• W4380082565 creator A5026641386 @default.
• W4380082565 creator A5027193786 @default.
• W4380082565 creator A5037105339 @default.
• W4380082565 creator A5045486705 @default.
• W4380082565 creator A5048609005 @default.
• W4380082565 creator A5060741746 @default.
• W4380082565 creator A5061466414 @default.
• W4380082565 creator A5065181560 @default.
• W4380082565 creator A5069441736 @default.
• W4380082565 creator A5077820287 @default.
• W4380082565 creator A5080726284 @default.
• W4380082565 creator A5088962433 @default.
• W4380082565 creator A5090761384 @default.
• W4380082565 date "2023-06-01" @default.
• W4380082565 modified "2023-10-14" @default.
• W4380082565 title "Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study" @default.
• W4380082565 doi "https://doi.org/10.1002/hon.3164_306" @default.
• W4380082565 hasPublicationYear "2023" @default.
• W4380082565 type Work @default.
• W4380082565 citedByCount "0" @default.
• W4380082565 crossrefType "journal-article" @default.
• W4380082565 hasAuthorship W4380082565A5003078312 @default.
• W4380082565 hasAuthorship W4380082565A5005349514 @default.
• W4380082565 hasAuthorship W4380082565A5007004125 @default.
• W4380082565 hasAuthorship W4380082565A5012158679 @default.
• W4380082565 hasAuthorship W4380082565A5013007045 @default.
• W4380082565 hasAuthorship W4380082565A5020361669 @default.
• W4380082565 hasAuthorship W4380082565A5026641386 @default.
• W4380082565 hasAuthorship W4380082565A5027193786 @default.
• W4380082565 hasAuthorship W4380082565A5037105339 @default.
• W4380082565 hasAuthorship W4380082565A5045486705 @default.
• W4380082565 hasAuthorship W4380082565A5048609005 @default.
• W4380082565 hasAuthorship W4380082565A5060741746 @default.
• W4380082565 hasAuthorship W4380082565A5061466414 @default.
• W4380082565 hasAuthorship W4380082565A5065181560 @default.
• W4380082565 hasAuthorship W4380082565A5069441736 @default.
• W4380082565 hasAuthorship W4380082565A5077820287 @default.
• W4380082565 hasAuthorship W4380082565A5080726284 @default.
• W4380082565 hasAuthorship W4380082565A5088962433 @default.
• W4380082565 hasAuthorship W4380082565A5090761384 @default.
• W4380082565 hasBestOaLocation W43800825651 @default.
• W4380082565 hasConcept C126322002 @default.
• W4380082565 hasConcept C141071460 @default.
• W4380082565 hasConcept C143998085 @default.
• W4380082565 hasConcept C207103383 @default.
• W4380082565 hasConcept C2776694085 @default.
• W4380082565 hasConcept C2776755627 @default.
• W4380082565 hasConcept C2778476033 @default.
• W4380082565 hasConcept C2778559949 @default.
• W4380082565 hasConcept C2778720950 @default.
• W4380082565 hasConcept C2779338263 @default.
• W4380082565 hasConcept C2779429289 @default.
• W4380082565 hasConcept C2779725641 @default.
• W4380082565 hasConcept C2780653079 @default.
• W4380082565 hasConcept C44249647 @default.
• W4380082565 hasConcept C71924100 @default.
• W4380082565 hasConcept C90924648 @default.
• W4380082565 hasConceptScore W4380082565C126322002 @default.
• W4380082565 hasConceptScore W4380082565C141071460 @default.
• W4380082565 hasConceptScore W4380082565C143998085 @default.
• W4380082565 hasConceptScore W4380082565C207103383 @default.
• W4380082565 hasConceptScore W4380082565C2776694085 @default.
• W4380082565 hasConceptScore W4380082565C2776755627 @default.
• W4380082565 hasConceptScore W4380082565C2778476033 @default.
• W4380082565 hasConceptScore W4380082565C2778559949 @default.
• W4380082565 hasConceptScore W4380082565C2778720950 @default.
• W4380082565 hasConceptScore W4380082565C2779338263 @default.
• W4380082565 hasConceptScore W4380082565C2779429289 @default.
• W4380082565 hasConceptScore W4380082565C2779725641 @default.
• W4380082565 hasConceptScore W4380082565C2780653079 @default.
• W4380082565 hasConceptScore W4380082565C44249647 @default.
• W4380082565 hasConceptScore W4380082565C71924100 @default.
• W4380082565 hasConceptScore W4380082565C90924648 @default.
• W4380082565 hasIssue "S2" @default.
• W4380082565 hasLocation W43800825651 @default.
• W4380082565 hasOpenAccess W4380082565 @default.
• W4380082565 hasPrimaryLocation W43800825651 @default.
• W4380082565 hasRelatedWork W1792893193 @default.
• W4380082565 hasRelatedWork W1967766014 @default.
• W4380082565 hasRelatedWork W2119651556 @default.
• W4380082565 hasRelatedWork W2132500976 @default.
• W4380082565 hasRelatedWork W2213920779 @default.
• W4380082565 hasRelatedWork W2769690276 @default.
• W4380082565 hasRelatedWork W2935716814 @default.
• W4380082565 hasRelatedWork W4250500771 @default.
• W4380082565 hasRelatedWork W4308730717 @default.
• W4380082565 hasRelatedWork W3022403900 @default.
• W4380082565 hasVolume "41" @default.
• W4380082565 isParatext "false" @default.
• W4380082565 isRetracted "false" @default.

• next